Market Place
Sourcing Support
Renibus Therapeutics Announces Participation at Investor Conferences
24 Sep 2024 //
PR NEWSWIRE
Renibus Announces Presentation at Oppenheimer 34th Annual Healthcare Conference
07 Feb 2024 //
PR NEWSWIRE
Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1
09 Jan 2024 //
PR NEWSWIRE
Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1
25 Oct 2023 //
PR NEWSWIRE
Renibus Therapeutics Announces Participation at Upcoming Investor Conferences
10 Oct 2023 //
PR NEWSWIRE
Renibus Therapeutics Announces Final Close of Upsized Series B Financing
12 Sep 2023 //
PR NEWSWIRE
Texas biotech raises $47M to move heart surgery drug into pivotal study
18 Jul 2023 //
ENDPTS
Renibus Announces Breakthrough Therapy Designation from US FDA for RBT-1
11 Jul 2023 //
PR NEWSWIRE
Renibus Reports Positive Final Results from Ph2 Study of RBT-1
07 May 2023 //
PR NEWSWIRE
Renibus Announces Presentation at 22nd Annual Needham Healthcare Conference
05 Apr 2023 //
PR NEWSWIRE
Renibus Announces Presentation at Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
PR NEWSWIRE
Renibus Therapeutics Announces Participation in the SVB Securities Conference
30 Jan 2023 //
PR NEWSWIRE
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Ph2 Trial
05 Jan 2023 //
PR NEWSWIRE
Renibus’ cardiac surgery drug aces phase 2 trial
05 Jan 2023 //
FIERCE BIOTECH
Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as SVP
13 Dec 2022 //
PRNEWSWIRE
Renibus Presents Phase 2 Data: RBT-1 Improves Post-Operative Outcomes
07 Nov 2022 //
PRNEWSWIRE
Renibus Announces Participation in Multiple Upcoming Investor Conferences
05 Oct 2022 //
PRNEWSWIRE
Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial
15 Jun 2022 //
GLOBENEWSWIRE
Renibus Tx Expands Leadership Team, Announces Appointments of New CFO & CMO
02 Jun 2022 //
GLOBENEWSWIRE
Renibus Therapeutics Strengthens IP Position with Additional US Patent
13 Apr 2022 //
GLOBENEWSWIRE
Renibus Therapeutics Appoints Frank Stonebanks as CEO and $35M Series A Funding
15 Feb 2022 //
GLOBENEWSWIRE
Renibus Therapeutics Announces Presentations at the ASNK Week 2021
28 Oct 2021 //
GLOBENEWSWIRE
Renibus Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
11 Mar 2021 //
GLOBENEWSWIRE
Rénibus to Present Phase 1b Data on RBT-1 at Acute Kidney Injury
25 Feb 2021 //
GLOBENEWSWIRE
Renibus Announces Publication of Positive Results of RBT-3 Experimental
17 Feb 2021 //
GLOBENEWSWIRE
Renibus Announces Publication of Positive Results of RBT-3 Experimental
16 Feb 2021 //
GLOBENEWSWIRE
Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antivira
07 Oct 2020 //
GLOBENEWSWIRE
Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9
23 Jun 2020 //
GLOBENEWSWIRE
Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic
23 Jun 2020 //
PHARMACEUTICAL-TECHNOLOGY
